Grading results.

<p>Grading results.</p

Area under the curve (AUC) of risk models in different AMD severity stages.

<p>Area under the curve (AUC) of risk models in different AMD severity stages.</p

Multivariate regression model for each severity stage with results for SNPs rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> (data of other SNPs is shown in S3 Table).

<p>Multivariate regression model for each severity stage with results for SNPs rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> (data of other SNPs is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156778#pone.0156778.s003" target="_blank">S3 Table</a>).</p

Univariate regression analysis for SNPs rs10490924 in ARMS2 and rs1061170 in CFH in patients with unilateral nAMD and different severity stages of the fellow-eye.

<p>Univariate regression analysis for SNPs rs10490924 in ARMS2 and rs1061170 in CFH in patients with unilateral nAMD and different severity stages of the fellow-eye.</p

Demographics.

<p>Demographics.</p

Additional file 1: of Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial

SPIRIT 2013 Checklist. (DOC 101 kb

Distribution of single nucleotide polymorphisms rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> and trend test of AMD severity stages (data of other SNPs is shown in S1 Table).

<p>Distribution of single nucleotide polymorphisms rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> and trend test of AMD severity stages (data of other SNPs is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156778#pone.0156778.s001" target="_blank">S1 Table</a>).</p

Precision medicine for age-related macular degeneration: current developments and prospects

<p><b>Introduction</b>: With the aging population, diseases such as age-related macular degeneration (AMD) will become more prevalent. This will increase the demand for provision of care on affected individuals, society, and the health-care system. To develop the best, individually tailored treatment for every patient, however, remains challenging.</p> <p><b>Areas covered</b>: Recent identifications of interactions between environmental, lifestyle, genetic, and non-genetic factors opened the potential for developing personalized approaches for the prevention and treatment of AMD. In this review, we will discuss the implications of these interactions for early to late disease stage conversion, for neovascularization, and for cell atrophy. We will put the findings of recent studies within the context of the regulatory framework requirements surrounding the development of personalized medicine approach to AMD.</p> <p><b>Expert commentary</b>: Precision medicine is now at a stage that it has its theoretical framework in place for the management of risk for patients with AMD requiring early diagnosis and timely treatment as several key components for such an approach are now clearly identified and are being applied to clinical developments successfully.</p

Emulsification data from sonication experiment

<p>From manuscript:</p> <p>Development of emulsification resistant heavier-than-water tamponade using high molecular weight silicone oil polymers</p

Shear Data

<p>From manuscript: </p> <p>Development of emulsification resistant heavier-than-water tamponade using high molecular weight silicone oil polymers</p> <p> </p